AI Article Synopsis
- The study examined mortality rates in elderly prostate cancer patients treated with both radical prostatectomy (RP) and external beam radiation therapy (EBRT) compared to RP alone.
- After analyzing data from over 18,000 patients, results revealed that those treated with RP and EBRT had significantly higher rates of other cause mortality (OCM) and cancer-specific mortality (CSM) over 10 years.
- The findings suggest that the combination treatment may not be necessary for elderly patients, highlighting the importance of careful patient selection for such therapies.
Article Abstract
Background: To test for rates of other cause mortality (OCM) and cancer-specific mortality (CSM) in elderly prostate cancer (PCa) patients treated with the combination of radical prostatectomy (RP) and external beam radiation therapy (EBRT) versus RP alone, since elderly PCa patients may be over-treated.
Methods: Within the Surveillance, Epidemiology and End Results database (2004-2016), cumulative incidence plots, after propensity score matching for cT-stage, cN-stage, prostate specific antigen, age and biopsy Gleason score, and multivariable competing risks regression models (socioeconomic status, pathological Gleason score) addressed OCM and CSM in patients (70-79, 70-74, and 75-79 years) treated with RP and EBRT versus RP alone.
Results: Of 18,126 eligible patients aged 70-79 years, 2520 (13.9%) underwent RP and EBRT versus 15,606 (86.1%) RP alone. After propensity score matching, 10-year OCM rates were respectively 27.9 versus 20.3% for RP and EBRT versus RP alone (p < .001), which resulted in a multivariable HR of 1.4 (p < .001). Moreover, 10-year CSM rates were respectively 13.4 versus 5.5% for RP and EBRT versus RP alone. In subgroup analyses separately addressing 70-74 year old and 75-79 years old PCa patients, 10-year OCM rates were 22.8 versus 16.2% and 39.5 versus 24.0% for respectively RP and EBRT versus RP alone patients (all p < .001).
Conclusion: Elderly patients treated with RP and EBRT exhibited worrisome rates of OCM. These higher than expected OCM rates question the need for combination therapy (RP and EBRT) in elderly PCa patients and indicate the need for better patient selection, when combination therapy is contemplated.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/pros.24169 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
External beam radiation therapy versus radical prostatectomy for high-risk prostate cancer: protocol of the RECOVER study.
BMC Cancer
January 2025
Netherlands Comprehensive Cancer Organisation, Utrecht, the Netherlands.
Background: This paper describes the rationale and design of the RECOVER study. Currently, there is no consensus regarding the optimal treatment for high-risk, non-metastatic prostate cancer (PCa). The study primarily aims to evaluate and compare the impact of treatment with robot-assisted radical prostatectomy (RP) versus external beam radiation therapy (EBRT) with androgen deprivation therapy (ADT) for men with high-risk, non-metastatic PCa regarding health-related quality of life (HRQoL) and functional outcomes.
View Article and Find Full Text PDFImpact of National Comprehensive Cancer Network Guidelines Inclusion of Level 1 Evidence on Insurance Denial for Randomized Controlled Trial Patients with Metastatic Spine Disease.
Rep Pract Oncol Radiother
December 2024
Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, United States.
Article Synopsis
- The study investigates the impact of recent evidence favoring stereotactic body radiation therapy (SBRT) over conventional external beam radiation therapy (EBRT) for treating metastatic spine disease on insurance approval rates.
- Before the National Comprehensive Cancer Network (NCCN) included this evidence in their guidelines, 25% of trial-eligible patients faced SBRT insurance denials; after inclusion, that rate dropped to 12.5% among a smaller group.
- Although the reduction in denials is notable, the small sample size makes it statistically insignificant, underscoring the need for more research and timely updates to clinical guidelines.
Intraoperative radiotherapy versus whole breast radiotherapy in early-stage breast cancer: a retrospective outcome analysis based on ASTRO guidelines on PBI.
Breast Cancer Res
December 2024
Department of Radiation Oncology, China Medial University Hospital, No. 2, Yude Rd., North Dist., Taichung City, 404327, Taiwan.
Background: Intraoperative radiotherapy (IORT) is a convenient treatment techniques for patients with early-stage breast cancer. We aimed to compare the outcome of IORT to that of whole-breast external beam radiotherapy (EBRT) in highly selected breast cancer patients based on the 2023 American Society for Radiation Oncology (ASTRO) Clinical Practice Guideline for Partial Breast Irradiation (PBI).
Patients And Methods: We reviewed patients who underwent breast-conserving surgery (BCS) and received either IORT or EBRT for early-stage breast cancer between 2014 and 2019.
Brachytherapy for Soft Tissue Sarcoma: Maintaining Local Control While Minimizing Complications.
J Surg Oncol
November 2024
Department of Orthopaedics, University of Miami Miller School of Medicine, Miami, Florida, USA.
Background: This study aims to assess the clinical and oncologic outcomes of high-dose brachytherapy (BRT) versus both preoperative and postoperative external beam radiation therapy (EBRT) in the setting of high-grade soft tissue sarcoma.
Methods: This is a retrospective cohort study of 144 patients treated surgically for soft tissue sarcoma at the same institution from 2010 to 2021. Patients treated for a soft tissue sarcoma with surgery and radiation therapy in the form of BRT, Neoadjuvant EBRT (Neo-EBRT) or adjuvant EBRT (AD-EBRT) were included.
A phase III randomised trial on the addition of a contact X-ray brachytherapy boost to standard neoadjuvant chemo-radiotherapy for organ preservation in early rectal adenocarcinoma: 5 year results of the OPERA trial.
Ann Oncol
November 2024
Centre Antoine Lacassagne, Université Côte d'Azur, Nice, France.
Background: The OPERA trial has shown that a contact X-ray brachytherapy 50 kV (CXB) boost with neoadjuvant chemoradiotherapy (NCRT) can increase organ preservation (OP) rate for early rectal adenocarcinoma (ADK) of low-mid rectum. We report the results after 5 years of follow-up.
Patients And Methods: OPERA was a multicentre, phase III trial that included operable patients (pts), with cT2-cT3b low-mid rectal ADK, tumours <5 cm, cN0 or cN1 <8 mm.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!